English English Explore our top-tier, laboratory-standardized bulk active raw materials. Fully compliant with European food safety directives, batch-tested via chiral HPLC, and ready for immediate customs clearance and delivery into Andorra la Vella and surrounding European manufacturing nodes.
An authoritative chemical analysis of Menaquinone-7 (MK-7) versus Menaquinone-4 (MK-4), stereoisomeric configuration (All-Trans vs. Cis-Isomers), and stability stabilization against mineral-induced degradation.
Menaquinone molecules exhibit geometric isomerism across their polyisoprenoid side chains. Only the all-trans stereoisomer fits precisely into the carboxylase enzyme complex required to activate Matrix Gla Protein (MGP) and Osteocalcin. Cis-isomers are biologically inert. BKYULA Biotech utilizes advanced enantioselective chiral HPLC validation to ensure every batch contains ≥98.5% all-trans MK-7, guaranteeing maximum biological half-life and target enzyme affinity.
Unprotected Menaquinone-7 degrades rapidly in the presence of alkaline mineral matrices such as calcium carbonate, magnesium oxide, or iron chelates. Our manufacturing facility in Xi'an employs specialized double-shell microencapsulation using gum acacia and modified food starches. This molecular barrier isolates the lipophilic menaquinone core from mechanical shear, ambient moisture, and reactive metallic cations, delivering a proven 36-month shelf life.
We supply both naturally fermented Menaquinone-7 derived from non-GMO Bacillus subtilis natto cultures and ultra-pure synthetic MK-7 synthesized from pure geraniol and farnesol precursors. The fermentation route delivers full European Novel Food status with complete allergen absence, while our synthetic menaquinone offers cost-effective, high-concentration powders (up to 98% pure crystals) without cross-contamination or residual soy proteins.
| Analytical Parameter | USP / European Pharmacopoeia Standard | BKYULA Menaquinone MK-7 Specification | Test Methodology |
|---|---|---|---|
| Active Assay (Menaquinone-7) | 1,000 ppm to 98.0% | Customized: 0.1%, 0.2%, 1.0%, 5.0%, and 98% Pure Powder | HPLC (Chiral Resolution) |
| Isomeric Configuration | ≥95.0% All-Trans | ≥98.5% All-Trans (Cis-isomer <1.5%) | Chiral Reversed-Phase HPLC |
| Appearance & Mesh Size | Off-white to pale yellow fine powder | Free-flowing powder, 100% pass 80 mesh (177 μm) | USP <786> Particle Size |
| Loss on Drying | ≤5.0% | ≤3.0% (Controlled moisture barrier) | Vacuum Oven (105°C, 4 hrs) |
| Heavy Metals (Pb, As, Cd, Hg) | Pb ≤3 ppm, As ≤1 ppm, Cd ≤1 ppm, Hg ≤0.1 ppm | Total <10 ppm; Pb <0.5 ppm, Cd <0.2 ppm, Hg <0.05 ppm | ICP-MS (Triple Quad) |
| Residual Solvents | Meets EP/ICH limits | Ethanol <500 ppm, Methanol/Acetone Not Detected | GC-HS (Headspace) |
| Microbiological Evaluation | Total Plate Count ≤1,000 CFU/g | TPC <500 CFU/g, Yeast & Mold <50 CFU/g, Salmonella Neg/25g | ISO 4833 / USP <2021> |
Andorra la Vella occupies a unique geoeconomic position between France and Spain, serving as a premier European tax-advantaged health haven, alpine sports medicine center, and private-label nutraceutical processing gateway.
With Andorra's global status in downhill skiing, trail running, and high-altitude endurance training, sports clinical laboratories based in Escaldes-Engordany and Andorra la Vella require bioactive ingredients that protect musculoskeletal architecture. Menaquinone-7 activates osteocalcin, directing systemic serum calcium into bone mineralization rather than vascular wall deposits. When combined with our Liposomal Vitamin D3, it dramatically mitigates micro-fracture risks and accelerates periosteal repair under chronic altitude stress.
The Principality of Andorra's favorable tax structure (IGI at 4.5%) has cultivated a thriving cross-border pharmaceutical and wellness retail market along Avinguda Meritxell. Contract formulators blend high-purity Vitamin K2 into drops, chewables, and hard capsules catering to visiting cross-border health consumers from France and Spain. BKYULA's bulk menaquinone powders enable localized compounding pharmacies to formulate clinical-strength bone and cardiovascular complexes at competitive cost thresholds.
Private wellness retreats and longevity medical institutions nestled in the Pyrenean valley specialize in anti-aging therapeutics. Inactive Matrix Gla Protein (ucMGP) is a primary circulating biomarker for vascular calcification and cardiovascular stiffness. Formulations blending 180 μg to 360 μg of our bio-fermented all-trans MK-7 ensure maximum carboxylation of MGP, preserving arterial wall elasticity and preventing arterial medial calcification in aging adult demographics.
Strategic market analysis of evolving consumer preferences, clean-label mandates, and regulatory oversight across the Pyrenean economic corridor.
Health authorities across Europe are discouraging isolated high-dose calcium supplementation due to documented arterial calcification risks. As a result, 92% of new bone-density formulations registered in the region now mandate the "Bone Triad": Calcium, Cholecalciferol (D3), and Menaquinone-7 (K2). Brands operating out of Andorra la Vella are actively replacing traditional synthetic Vitamin K1 (Phylloquinone) with bio-identical Menaquinone-7 to comply with EFSA Article 13(1) health claims regarding normal bone structure maintenance.
Traditional MK-7 fermentation relied on fermented soybeans (Natto), which triggered mandatory EU allergen disclosures. Modern Andorran procurement directors now stipulate non-soy, fermentation-derived or bio-identical synthetic menaquinone carried on prebiotic fiber bases, such as non-GMO acacia fiber or organic maltodextrin. Our allergen-free manufacturing protocols meet these criteria without requiring allergen warning labels on finished consumer packaging.
Andorran wellness innovators are increasingly integrating Vitamin K2 with metabolic adaptogens and botanical polyphenols. By formulating Menaquinone-7 alongside our Natural Saffron Extract for stress-induced vascular tone regulation or Organic Apple Cider Vinegar Powder for metabolic balance, formulators capture higher market margins while providing comprehensive cellular and vascular protection.
Operating from our high-precision botanical and vitamin synthesis facility in Xi'an, China, BKYULA Biotech combines 15 years of technical refinement with audited compliance systems verified by SGS Group.
Our operations have been audited on-site and verified by the SGS Group. We operate under stringent global food safety and quality management architectures, holding active registrations for ISO 9001:2015, ISO 22000, HACCP, HALAL, KOSHER, and feed-grade FAMI-QS. Every single export lot is accompanied by a full-panel Certificate of Analysis (COA), heavy metals screening, and residual solvent clearances.
We maintain our own dedicated in-house analytical testing suite equipped with Agilent & Shimadzu High-Performance Liquid Chromatography (HPLC) towers, UV Spectrophotometers, loss-on-drying vacuum chambers, and ISO Class 7 cleanrooms for bio-burden assays. Menaquinone is uniquely vulnerable to non-separation of isomers during standard C18 chromatography; our dedicated chiral separation columns ensure zero false positives for cis-isomers.
We eliminate traditional bulk supply bottlenecks by offering flexible Minimum Order Quantities starting from 1 kg for standard menaquinone powders and from 1 gram for high-potency 98% pure crystals. Furthermore, our turnkey OEM/ODM department supports Andorran brand owners with premix formulation, rotary tablet pressing, powder stick-packing, blister packing, and full private-label packaging.
Clear answers regarding customs clearance, cross-border transit via Spain/France, analytical verification, and formulation compatibility.
Partner directly with China's leading certified botanical and vitamin synthesis facility. Submit your formulation assay target, target application, and regulatory parameters to our technical export team today.
